ghadmin
Guardant Health Applauds Congressional Letter Calling for HHS Action to Improve USPSTF Process to Increase Access to Cancer Screenings
Palo Alto, Calif. – July 25, 2022 – Guardant Health, a leading precision oncology company, applauds Congresswoman Anna Eshoo (D-CA) and Energy
Steve E. Krognes Joins Guardant Health Board of Directors
Mr. Krognes is a professional independent board member in the biotech and life science sector. He currently serves as a director at Denali Therapeutics Inc., Gritstone bio, Inc. and RLS Global AB, and previously served on the board at Corvus Pharmaceuticals, Inc.
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture
Guardant Health today announced it has purchased the remaining shares of Guardant Health AMEA, Inc., held by SoftBank and its affiliates, giving the company full control over operations throughout the Asia, Middle East and Africa region.
First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d’Hebron Institute of Oncology
The first blood-based cancer testing services in Europe based on Guardant Health’s industry-leading digital sequencing platform are now available at the VHIO liquid biopsy testing facility in Barcelona
Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Guardant Health, Inc. announced today it will present new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 in Chicago.
Guardant Health Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-of-its Kind Prospective Study at Digestive Disease Week 2022
Guardant Health, Inc. today announced data showing its blood-based multimodal test achieved clinically significant thresholds of sensitivity and specificity in detecting colorectal cancer (CRC).
Guardant Health Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults
Highly sensitive Shield test offers convenient screening method that can be completed with simple blood draw, helping overcome barriers to compliance
